1. Home
  2. ARAY vs IFRX Comparison

ARAY vs IFRX Comparison

Compare ARAY & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Accuray Incorporated

ARAY

Accuray Incorporated

HOLD

Current Price

$0.38

Market Cap

55.2M

Sector

Health Care

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$2.58

Market Cap

66.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARAY
IFRX
Founded
1990
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.2M
66.0M
IPO Year
2006
2017

Fundamental Metrics

Financial Performance
Metric
ARAY
IFRX
Price
$0.38
$2.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$3.50
$6.25
AVG Volume (30 Days)
3.3M
3.0M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
87.50
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.58
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$0.74
52 Week High
$2.10
$2.95

Technical Indicators

Market Signals
Indicator
ARAY
IFRX
Relative Strength Index (RSI) 51.72 63.78
Support Level $0.34 $0.96
Resistance Level $0.48 $2.95
Average True Range (ATR) 0.05 0.27
MACD 0.01 -0.02
Stochastic Oscillator 84.57 46.88

Price Performance

Historical Comparison
ARAY
IFRX

About ARAY Accuray Incorporated

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: